Sana Biotechnology (NASDAQ:SANA – Get Free Report) and VectivBio (NASDAQ:VECT – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations.
Risk & Volatility
Sana Biotechnology has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Sana Biotechnology and VectivBio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sana Biotechnology | 0 | 3 | 2 | 0 | 2.40 |
| VectivBio | 0 | 2 | 3 | 0 | 2.60 |
Valuation & Earnings
This table compares Sana Biotechnology and VectivBio’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sana Biotechnology | N/A | N/A | -$269.48 million | ($1.89) | -2.03 |
| VectivBio | $27.34 million | N/A | -$93.74 million | N/A | N/A |
VectivBio has higher revenue and earnings than Sana Biotechnology.
Insider & Institutional Ownership
68.4% of Sana Biotechnology shares are held by institutional investors. 34.9% of Sana Biotechnology shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Sana Biotechnology and VectivBio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sana Biotechnology | N/A | -73.07% | -42.55% |
| VectivBio | N/A | N/A | N/A |
Summary
VectivBio beats Sana Biotechnology on 6 of the 10 factors compared between the two stocks.
About Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.
About VectivBio
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Receive News & Ratings for Sana Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sana Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
